Government Price Reporting Implications of Value-Based Arrangements: Supporting Increased Quality and Better Outcomes
Prompted by the interest from policymakers, pharmaceutical manufacturers are exploring contracting and pricing strategies that base the price of a drug on measures of the drug’s performance, such as patient outcomes. Such value-based arrangements can pose unique government price reporting challenges. The price reporting requirements generally focus on capturing a per-unit price, while many value-based arrangements effectively avoid a per-unit price in favor of longer-term, broader valuation approaches. This session will discuss possible value-based arrangements and their potential price reporting implications under the Medicaid Drug Rebate, Medicare Part B, and 340B Programs, and explore possible avenues for implementing value-based arrangements in light of price reporting requirements.